Literature DB >> 27007275

Evaluation of estimation, prediction and inference for autocorrelated latent variable modeling of binary data-a simulation study.

Matthew M Hutmacher1.   

Abstract

Longitudinal models of binary or ordered categorical data are often evaluated for adequacy by the ability of these to characterize the transition frequency and type between response states. Drug development decisions are often concerned with accurate prediction and inference of the probability of response by time and dose. A question arises on whether the transition probabilities need to be characterized adequately to ensure accurate response prediction probabilities unconditional on the previous response state. To address this, a simulation study was conducted to assess bias in estimation, prediction and inferences of autocorrelated latent variable models (ALVMs) when the transition probabilities are misspecified due to ill-posed random effects structures, inadequate likelihood approximation or omission of the autocorrelation component. The results may be surprising in that these suggest that characterizing autocorrelation in ALVMs is not as important as specifying a suitably rich random effects structure.

Keywords:  Autocorrelation; Generalized nonlinear mixed-effects models; Latent variable; Probit

Mesh:

Year:  2016        PMID: 27007275     DOI: 10.1007/s10928-016-9471-3

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  10 in total

1.  Extending the latent variable model for extra correlated longitudinal dichotomous responses.

Authors:  Matthew M Hutmacher; Jonathan L French
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-22       Impact factor: 2.745

2.  The analysis of binary longitudinal data with time-dependent covariates.

Authors:  Matthew W Guerra; Justine Shults; Jay Amsterdam; Thomas Ten-Have
Journal:  Stat Med       Date:  2012-01-13       Impact factor: 2.373

3.  Avoiding bias in mixed model inference for fixed effects.

Authors:  Matthew J Gurka; Lloyd J Edwards; Keith E Muller
Journal:  Stat Med       Date:  2011-07-12       Impact factor: 2.373

4.  Latent variable indirect response modeling of categorical endpoints representing change from baseline.

Authors:  Chuanpu Hu; Zhenhua Xu; Alan M Mendelsohn; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-30       Impact factor: 2.745

5.  Evaluation of bias, precision, robustness and runtime for estimation methods in NONMEM 7.

Authors:  Åsa M Johansson; Sebastian Ueckert; Elodie L Plan; Andrew C Hooker; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-05-07       Impact factor: 2.745

6.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

7.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

8.  A nonstationary Markov transition model for computing the relative risk of dementia before death.

Authors:  Lei Yu; William S Griffith; Suzanne L Tyas; David A Snowdon; Richard J Kryscio
Journal:  Stat Med       Date:  2010-03-15       Impact factor: 2.373

9.  A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis.

Authors:  B D Lacroix; M R Lovern; A Stockis; M L Sargentini-Maier; M O Karlsson; L E Friberg
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

10.  Exposure-response modeling of clinical end points using latent variable indirect response models.

Authors:  C Hu
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-06-04
  10 in total
  2 in total

1.  Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.

Authors:  Chuanpu Hu; Omoniyi J Adedokun; Liping Zhang; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-30       Impact factor: 2.745

2.  Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's disease.

Authors:  Chuanpu Hu; Omoniyi J Adedokun; Yang Chen; Philippe O Szapary; Christopher Gasink; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-16       Impact factor: 2.745

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.